Asset Acquisition - Summary of Fair Value of the Consideration Transferred to the Net Assets Acquired and Liabilities Assumed with the Excess Recorded to Loss on Acquisition (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | |||||
|---|---|---|---|---|---|---|---|
May 18, 2026 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||
| Liabilities assumed: | |||||||
| Gain on Orphai Acquisition | $ (1,305) | $ 0 | $ (1,305) | $ 0 | |||
| Orphai Therapeutics [Member] | |||||||
| Assets acquired: | |||||||
| Cash and cash equivalents | $ 8,001 | ||||||
| Prepaid expenses and other current expenses | 451 | ||||||
| In-process research and development | [1] | 59,000 | |||||
| Total assets acquired | 67,452 | ||||||
| Liabilities assumed: | |||||||
| Trade payables | (3,097) | ||||||
| Accrued expenses and other current liabilities | (6,186) | ||||||
| Total liabilities assumed | (9,283) | ||||||
| Fair value of assets acquired and liabilities assumed | 58,169 | ||||||
| Gain on Orphai Acquisition | $ (1,305) | ||||||
| |||||||